On 27 June 2016, orphan designation (EU/3/16/1672) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride (also known as CC-122) for the treatment of diffuse large B-cell lymphoma.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in January 2019.
Treatment of diffuse large B-cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
EU/3/16/1672: Public summary of opinion on orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride for the treatment of diffuse large B-cell lymphoma (PDF/126.45 KB)
First published: 26/07/2016
Last updated: 26/07/2016
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: